JUN 10, 2019 12:10 PM PDT

Tart Cherry and Pain Management in Breast Cancer Patients

WRITTEN BY: Nouran Amin

In patients with non-metastatic breast cancer, treated with aromatase inhibitors, tart cherry was found to reduce the musculoskeletal effects of the drug. The findings were based on a clinical trial by researchers at Marshall University Joan C. Edwards School of Medicine and Edwards Comprehensive Cancer Center.

"The flavonoids and anthocyanins in tart cherry have anti-inflammatory properties and may be playing a role in reducing the side effects of joint pain and muscles aches, although etiology of aromatase-induced arthralgias remain unclear at this time," said principal investigator Maria Tria Tirona, M.D., professor of hematology-oncology at the Marshall University Joan C. Edwards School of Medicine and director of medical oncology at Edwards Comprehensive Cancer Center. "There was a statistically significant difference in the pain levels experienced by patients in the group that received the tart cherry concentrate compared to the placebo group."

Currently, aromatase inhibitors (AIs) therapeutics are the standard treatment option for hormone receptor-positive breast cancer in postmenopausal women. The drug can prevent reemergence of the disease by blocking the activity of aromatase, an enzyme that is responsible for converting androgens to estrogens. However, an estimated half of all patients treated with AIs will suffer from joint and muscle pain. That particular pain is known as aromatase inhibitor induced arthralgia and at times can often be so painful and debilitating that it leads to patients to stop treatmetns earlyleading to patients stopping treatments.

Learn more about aromatase inhibitors (AIs):

But, in the randomized, double-blind trial of 60 participants, the consumption of 1 ounce of tart cherry concentrate in 8 ounces of water daily for six weeks with a placebo group in women was compared with stage 1, 2 or 3 non-metastatic breast cancer.

Patients were required to document their pain intensity at the beginning of the trial, weekly and at study completion. Upon completion, 34.7% of patients reported a mean decrease in pain compared to just 1.4% in the placebo group.

Source: Joan C. Edwards School of Medicine

 

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 13, 2020
Cancer
APR 13, 2020
The Unexpected Role of Mono in Cancer Progression
In the past, the go-to drugs have always been small molecules. These small molecules would interact with the cell and ac ...
APR 21, 2020
Cannabis Sciences
APR 21, 2020
Is CBD Effective Against Women's Health Issues?
Products containing cannabidiol (CBD) are increasingly known as a natural and effective way to handle a wide range of wo ...
APR 08, 2020
Neuroscience
APR 08, 2020
Study Catalogs Mouse Facial Expressions
It's easy to gauge a dog or cat's emotion by reading their facial expression, but the same has been historically ...
APR 23, 2020
Drug Discovery & Development
APR 23, 2020
Making Recombination-Protein Drugs Cost Effective
  In a study published in Nature Communications, scientists used genome-editing techniques to eliminate up to 70 pe ...
MAY 23, 2020
Cancer
MAY 23, 2020
A New Biomarker to Identify a Triple Negative Breast Cancer Prognosis
Breast cancer, one of the most common cancers in the world, are commonly separated into one of several sub-types. These ...
MAY 25, 2020
Genetics & Genomics
MAY 25, 2020
FDA Approves the First Treatment for Neurofibromatosis 1
In a major breakthrough, the Food and Drug Administration has approved a treatment for a genetic disorder called neurofi ...
Loading Comments...